But researchers found that semaglutide, the scientific name of Ozempic ... other diabetes treatments such as insulin, metformin, SGLT2 inhibitors, and older GLP-1 drugs. They also found that ...

FSGS presents significant management challenges, with nephrologists (n=102) estimating that, on average, nearly half of their patients are not optimally managed with existing therapies. Spherix’s ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

So what is semaglutide and who uses it in India? Semaglutide belongs to the class of drugs called Glucagon-like peptide-1 ...

IDF creating new Type 2 diabetes guidelines with global experts, focusing on patient-centered care and global accessibility.

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

Good morning, and welcome to the Travere Therapeutics' Third Quarter 2024 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over ...

Meanwhile, the rare disease portfolio acquired along with Alexion grew 6% to $1.8 billion, with a 23% increase for complement C5 inhibitor Ultomiris ... than the overall SGLT2 market in most ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.